Table II.
Study parameter | Value |
---|---|
Age in years (Standard deviation) | 5.9 (4.4) |
Age at diagnosis (standard deviation) | 0.2 (2.9) |
Age-wise distribution | |
< 2 years | 5 (14.2%) |
2–5 years | 11 (31.4%) |
5–10 years | 13 (37.1%) |
> 10 years | 6 (17.1) |
Sex distribution (M : F) | 1.1 : 1 (19/16) |
Tanner’s stage | |
Stage 1 | 26 (74.2%) |
Stage 2 | 3 (8.5%) |
Stage 3 | 2 (5.7%) |
Stage 4 | 2 (5.7%) |
Stage 5 | 2 (5.7%) |
Type of CAH | |
Salt wasting | 22 (62.8%) |
Simple virilizing | 12 (34.2%) |
Non-classical | 1 (2.8%) |
Median 17 OHP (ng/ml) at presentation (range) | 39 ng/ml (0.26-832) |
Median 17 OHP (ng/ml) diagnosed by NBS (range) | 237.5 ng/ml (29-406) |
Hypotensive at presentation | 6 (17.1%) |
Height Z-score at presentation (percentage short) | –0.12 ±2.0 (22%) |
Weight Z-score at presentation | –0.45 ±1.9 |
BMI Z-score at presentation (percentage with wasting) | –0.43 ±1.6 (22%) |
17 OHP (ng/ml) at follow-up (median) | 3.52 ng/ml |
BP at follow up (percentage hypotensive) | 2 (5.7%) |
SBP median (mmHg) | 104 ±17 |
DBP median (mmHg) | 70 ±11 |
Height Z-score at follow-up (percentage short) | –0.12 ±1.6 (20%) |
Salt wasting | –0.15 ±1.6 (22.7%) |
Simple virilising | –0.03 ±1.6 (16.6%) |
Weight Z-score at follow-up | –0.09 ±1.6 |
Salt wasting | –0.02 ±1.6 |
Simple virilising | –0.16 ±1.6 |
BMI Z-score at follow-up (percentage overweight and obesity) | –0.50 ±1.0 (17.1% and 25%) |
Severity of virilization severe | |
Before 2018 | |
Prader Stage 0 | 0 |
Prader Stage 1 | 1 |
Prader Stage 2 | 1 |
Prader Stage 3 | 2 |
Prader Stage 4 | 3 |
Prader Stage 5 | 0 |
After 2018 | |
Prader Stage 0 | 1 |
Prader Stage 1 | 0 |
Prader Stage 2 | 1 |
Prader Stage 3 | 4 |
Prader Stage 4 | 3 |
Prader Stage 5 | 0 |
CAH – congenital adrenal hyperplasia; 17-OHP – 17-hydroxyprogesterone; NBS – newborn screening; BMI – body mass index; BP – blood pressure; SBP – systolic blood pressure; DBP – diastolic blood pressure